Literature DB >> 15159642

Executive function impairment in early-treated PKU subjects with normal mental development.

V Leuzzi1, M Pansini, E Sechi, F Chiarotti, Cl Carducci, G Levi, I Antonozzi.   

Abstract

Executive functions were studied in 14 early and continuously treated PKU subjects (age 10.8 years, range 8-13) in comparison with controls matched for IQ, sex, age and socioeconomic status. Brain MRI examination was normal in all PKU patients. Neuropsychological evaluation included Wisconsin Card Sorting Test, Rey-Osterreith Complex Figure Test, Elithorn's Perceptual Maze Test, Weigl's Sorting Test, Tower of London, Visual Search and Motor Motor Learning Test. Whatever the IQ, PKU subjects performed worse than controls in tests exploring executive functions. Subgrouping the PKU subjects according to the quality of dietary control for the entire follow-up period (using 400 micromol/L as cut-off value for blood phenylalanine (Phe) concentration) showed that patients with worse dietary control performed more poorly than both the PKU group with the best dietary control and the control group. However, a mild impairment of executive functions was still found in PKU patients with a good dietary control (Phe <400 micromol/L) compared to controls. Concerning the PKU group as a whole, no linear correlation was found between neuropsychological performance and historical and concurrent biochemical parameters. We conclude that (a) PKU patients, even when treated early, rigorously and continuously, show an impairment of frontal lobe functions; (b) a protracted exposure to moderately high levels of Phe can affect frontal lobe functions independently of the possible effect of the same exposure on IQ; (c) in order to reduce the risk of frontal lobe dysfunction, the target of dietary therapy should be to maintain blood Phe concentration below 400 micromol/L.

Entities:  

Mesh:

Year:  2004        PMID: 15159642     DOI: 10.1023/B:BOLI.0000028781.94251.1f

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  33 in total

1.  Prefrontal regions play a predominant role in imposing an attentional 'set': evidence from fMRI.

Authors:  M T Banich; M P Milham; R A Atchley; N J Cohen; A Webb; T Wszalek; A F Kramer; Z Liang; V Barad; D Gullett; C Shah; C Brown
Journal:  Brain Res Cogn Brain Res       Date:  2000-09

2.  Some observations on the dietary treatment of phenylketonuria.

Authors:  M E O'Flynn; D Hsia
Journal:  J Pediatr       Date:  1968-02       Impact factor: 4.406

3.  Dopaminergic drugs improve human visual contrast sensitivity.

Authors:  L Domenici; C Trimarchi; M Piccolino; A Fiorentini; L Maffei
Journal:  Hum Neurobiol       Date:  1985

4.  Abilities and neural mechanisms underlying AB performance.

Authors:  A Diamond
Journal:  Child Dev       Date:  1988-04

5.  Neuropsychology of early-treated phenylketonuria: specific executive function deficits.

Authors:  M C Welsh; B F Pennington; S Ozonoff; B Rouse; E R McCabe
Journal:  Child Dev       Date:  1990-12

6.  Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria.

Authors:  M Luciana; J Sullivan; C A Nelson
Journal:  Child Dev       Date:  2001 Nov-Dec

7.  Correlation between intelligence test scores and executive function measures.

Authors:  A Ardila; D Pineda; M Rosselli
Journal:  Arch Clin Neuropsychol       Date:  2000-01       Impact factor: 2.813

8.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

9.  Early-treated phenylketonuria: neuropsychologic consequences.

Authors:  R L Brunner; M K Jordan; H K Berry
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

10.  Impaired use of organizational strategies in free recall following frontal lobe damage.

Authors:  F B Gershberg; A P Shimamura
Journal:  Neuropsychologia       Date:  1995-10       Impact factor: 3.139

View more
  29 in total

1.  Variability in phenylalanine control predicts IQ and executive abilities in children with phenylketonuria.

Authors:  Anna Hood; Dorothy K Grange; Shawn E Christ; Robert Steiner; Desirée A White
Journal:  Mol Genet Metab       Date:  2014-01-31       Impact factor: 4.797

2.  Autism Spectrum Disorder and Phenylketonuria: Dyzygotic Twins with Double Syndrome.

Authors:  Esra Demirci
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

3.  Pyruvate and creatine prevent oxidative stress and behavioral alterations caused by phenylalanine administration into hippocampus of rats.

Authors:  Simone Luisa Berti; Guilherme Marmontel Nasi; Cristina Garcia; Fernanda Luz de Castro; Michely Lopes Nunes; Denise Bertin Rojas; Tarsila Barros Moraes; Carlos Severo Dutra-Filho; Clóvis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2011-11-19       Impact factor: 3.584

Review 4.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

5.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

6.  Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases.

Authors:  T Mlčoch; R Puda; P Ješina; M Lhotáková; Š Štěrbová; T Doležal
Journal:  Eur J Clin Nutr       Date:  2017-06-28       Impact factor: 4.016

7.  Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.

Authors:  Nicola Longo; Cary O Harding; Barbara K Burton; Dorothy K Grange; Jerry Vockley; Melissa Wasserstein; Gregory M Rice; Alejandro Dorenbaum; Jutta K Neuenburg; Donald G Musson; Zhonghua Gu; Saba Sile
Journal:  Lancet       Date:  2014-04-14       Impact factor: 79.321

8.  Executive dysfunction in treated phenylketonuric patients.

Authors:  Bahare Azadi; Arshia Seddigh; Mehdi Tehrani-Doost; Javad Alaghband-Rad; Mahmoud Reza Ashrafi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-16       Impact factor: 4.785

Review 9.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 10.  Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause?

Authors:  F J van Spronsen; Marieke Hoeksma; Dirk-Jan Reijngoud
Journal:  J Inherit Metab Dis       Date:  2009-01-13       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.